Glenmark Pharmaceuticals Ltd has reported consolidated net profit growth of 15.52 per cent to Rs 94.07 crore for the third quarter ended December 31, 2009, over the corresponding period last year.

Cadila needs to prove of VLP technology safe before conducting clinical trials, says DCGI

An experimental vaccine against chikungunya virus infection has shown promise, according to reserachers at the National Institute of Allergy and Infectious Diseases (NIAID).

The government of India has brought into effect stricter norms for obtaining No Objection Certificates (NOCs) for pharmaceutical exporters.

Early Result Pregnancy Test can determine pregnancy up to six days